Gosset Ownership
Private
Employees
~1
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Goldenrod Therapeutics General Information
Goldenrod is developing 11h, a small molecule that has shown evidence in various disease states and is preparing for IND-enabling studies. Their compounds are designed to be orally bioavailable and brain-penetrant while avoiding adverse events like nausea associated with current inhibitors.
Contact Information
Primary Industry
Biotech
Corporate Office
Houston, Texas
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Goldenrod Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Jun 5, 2026 | $6.5M | Completed | Preclinical |
To view Goldenrod Therapeutics's complete valuation and funding history, request access »